Presented By

Presented By

Continuing Education

Join the RESPTREC family for lifelong learning opportunities and mentorship.


CCCEP Logo

CCCEP: The Education, COPD and Asthma courses have been accredited by Canadian Council on Continuing Education in Pharmacy. Pharmacists have been involved in development of the curricula and review of the content.

The Canadian Council on Continuing Education in Pharmacy has confirmed accreditation as follows:

  • Education for Chronic Disease Management Course - 27.50 CEUs
  • COPD Management Course - 21.50 CEUs
  • Asthma Management Course - 17.50 CEUs

Resources: Download or order RESPTREC resources:

  • Asthma Medications Brochure
  • COPD Medications Brochure
  • Delivery Device Instructions
  • Delivery Device Mastery Sheets

Webinars: Webinars on the most recent research, position papers, guidelines, topics are presented by leading experts in the field quarterly. 15 sites across western Canada participate. For those graduates who are unable to join a live session can access the presentations on-line, following the Webinar. Questions are posted following viewing of the presentation and a continuing education certificate can be printed for your records.


Current News

For your convenience RESPTREC provides links to research articles, announcements, studies and other news updates which are posted daily onto the website. Reading these articles can be used towards recertification and continuing education.

Watch for upcoming opportunities!

The risk of mycobacterial infections associated with inhaled corticosteroid use
Sep 21, 2017

Inhaled corticosteroid (ICS) use is associated with an increased risk of pneumonia. A study found that ICS use is also associated with an increased risk of nontuberculous mycobacterial pulmonary disease 


COPD patients with high symptom burden or CAT ≥10 have an increased likelihood of experiencing work productivity loss
Sep 21, 2017

A Canadian study shows that the burden of COPD goes beyond its impact on the health care system. There is potential for a significant burden at the workplace, even among individuals with mild to moderate airflow obstruction.


The paradoxes of asthma management: time for a new approach?
Sep 21, 2017

Studies confirm that when asthma symptoms worsen, most patients increase short-acting β2-agonist use, instead of using controller medication. This behaviour might be attributable to several paradoxes in the current asthma treatment approach.


“I have lost in every facet of my life”: the hidden burden of severe asthma
Sep 21, 2017

Severe asthma imposes long-term, debilitating burdens and should be considered differently to milder disease. There is an urgent need to improve practical and emotional support services for patients and their carers.


European Respiratory Society guidelines for the management of adult bronchiectasis
Sep 21, 2017

Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations. The ERS guidelines for the management of adult bronchiectasis describe the appropriate investigation and treatment strategies determined by a systematic review of the literature.


Prevention of COPD exacerbations: an ERS/ATS guideline
Sep 21, 2017

This document provides clinical recommendations for the prevention of COPD exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society.


Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis
Sep 21, 2017

The peripheral blood 52-gene expression signature is predictive of outcome in patients with idiopathic pulmonary fibrosis


Choosing wisely: The CTS list of six things that physicians and patients should question
Sep 21, 2017

Choosing Wisely is a campaign that aims to help clinicians and patients engage in conversations regarding unnecessary tests and treatments, in order to improve quality of care and reduce waste in healthcare.


Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Sep 19, 2017

The use of pirfenidone in IPF patients was associated with lower risk of nonelective respiratory-related hospitalization than placebo (7% vs 12%) over the course of 1 year. The effect of pirfenidone on death after hospitalization is uncertain.


Asthma in the elderly and late-onset adult asthma
Sep 19, 2017

Elderly asthmatics are at a higher risk for morbidity and mortality from their asthma than younger patients. There are important age-related physiologic and immunologic changes that complicate the presentation, diagnosis, and management of asthma in the aged population. 


Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand
Sep 19, 2017

This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population


Spirometry training courses: Content, delivery and assessment
Sep 19, 2017

The primary outcome of spirometry training courses should be to enable participants to perform spirometry to international best practice, including testing of subjects, quality assurance and interpretation of results: Australian and New Zealand Society of Respiratory Science position statement 


Does limb partitioning and positioning affect acute cardiorespiratory responses during strength exercises in patients with COPD?
Sep 19, 2017

Double-arm elevation above shoulder level appears to be more challenging than other strength exercise variations. Partitioning exercises and limb position may reduce perceived exertion during training.


Lung function in relation to farm dwelling and farming activities in rural dwelling children
Sep 19, 2017

A stufy of the association between lung function and rural exposures found that differences in lung function were seen between children living on a farm and not living on a farm in rural areas and certain farming activities, specifically emptying grain bins, where lung function was generally better in…


Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD
Sep 19, 2017

In patients with stable COPD, LAMA were associated with a greater reduction in acute exacerbations and fewer adverse effects compared with LABA. There were no significant differences in trough FEV1, TDI and SGRQ scores.


RESPTREC™    Advance your skills. Be a leader. | Twitter Facebook